| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41409-020-0834-4 |
| P698 | PubMed publication ID | 32071418 |
| P50 | author | Ivan S Moiseev | Q85770882 |
| Yu A Serov | Q89767648 | ||
| P2093 | author name string | E V Morozova | |
| L S Zubarovskaya | |||
| T A Bykova | |||
| E A Surkova | |||
| S V Lapin | |||
| O V Paina | |||
| S I Moiseev | |||
| G G Rodionov | |||
| B V Afanasyev | |||
| O V Pirogova | |||
| A A Osipova | |||
| A A Dotsenko | |||
| A G Smirnova | |||
| A N Galimov | |||
| E A Kulagin | |||
| E S Borzenkova | |||
| K A Ekushov | |||
| N Yu Tcvetkov | |||
| O U Klimova | |||
| P V Kozhokar | |||
| T A Rudakova | |||
| Ya V Gudognikova | |||
| P2860 | cites work | Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials | Q50115590 |
| Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. | Q50798708 | ||
| GVHD: biology matters | Q59333340 | ||
| Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis | Q64112799 | ||
| Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study | Q84215346 | ||
| Simultaneous quantification of ruxolitinib and nilotinib in rat plasma by LC-MS/MS: application to a pharmacokinetic study | Q87343077 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results | Q90401852 | ||
| Disability Related to Chronic Graft-versus-Host Disease | Q91026175 | ||
| Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study | Q91174334 | ||
| How I treat refractory chronic graft-versus-host disease | Q91185109 | ||
| Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. | Q31893507 | ||
| Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone | Q33342878 | ||
| Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial | Q33439559 | ||
| Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients | Q33440405 | ||
| Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement | Q33622648 | ||
| Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation | Q33718837 | ||
| The biology of graft-versus-host disease: experimental systems instructing clinical practice | Q33917175 | ||
| An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 | ||
| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report | Q34474243 | ||
| A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality | Q35177453 | ||
| Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T cells in acute GVHD. | Q35561300 | ||
| First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation | Q36113205 | ||
| B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways | Q36250962 | ||
| Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group repor | Q36554724 | ||
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey | Q36862931 | ||
| Pilot study of lithium to restore intestinal barrier function in severe graft-versus-host disease | Q38619812 | ||
| 1994 Consensus Conference on Acute GVHD Grading | Q39513397 | ||
| Corruption of dendritic cell antigen presentation during acute GVHD leads to regulatory T-cell failure and chronic GVHD. | Q39659749 | ||
| Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria | Q41554713 | ||
| The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 | ||
| Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation. | Q46236950 | ||
| Ibrutinib for chronic graft-versus-host disease after failure of prior therapy | Q46428638 | ||
| Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease | Q49724160 | ||
| P921 | main subject | ruxolitinib | Q7383611 |
| P577 | publication date | 2020-02-18 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults |
Search more.